What is the recommended dosing of Tadalafil (Cialis) in patients with End-Stage Renal Disease (ESRD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the FDA Drug Label

Tadalafil should be limited to 5 mg not more than once in every 72 hours in patients with creatinine clearance less than 30 mL/min or end-stage renal disease on hemodialysis Tadalafil tablets for once daily use is not recommended in patients with creatinine clearance less than 30 mL/min Creatinine clearance less than 30 mL/min or on hemodialysis: The maximum dose is 5 mg not more than once in every 72 hours Creatinine clearance less than 30 mL/min or on hemodialysis: Tadalafil tablets for once daily use is not recommended

The recommended dosing of tadalafil for patients with ESRD is:

  • For use as needed: 5 mg not more than once in every 72 hours
  • For once daily use: not recommended 1, 1

From the Research

For patients with end-stage renal disease (ESRD) requiring Cialis (tadalafil), the recommended initial dose is 5 mg once daily, with a maximum dose of 10 mg not to exceed once every 48 hours. This reduced dosing is necessary because tadalafil clearance is significantly decreased in ESRD patients, leading to approximately doubled drug exposure compared to individuals with normal renal function 2. The most recent and highest quality study, published in 2017, supports the use of low-dose tadalafil in patients undergoing hemodialysis with end-stage renal disease, demonstrating improved erectile and ejaculatory function with acceptable adverse effects 2. Key points to consider when prescribing tadalafil to ESRD patients include:

  • Hemodialysis contributes minimally to tadalafil elimination, removing less than 1% of the dose during a dialysis session, so supplemental doses after dialysis are not required
  • Patients should take tadalafil at the same time each day when possible for consistent blood levels
  • Side effects to monitor include headache, dyspepsia, back pain, and hypotension, particularly if the patient is taking nitrates which are absolutely contraindicated with tadalafil
  • The reduced dosing schedule balances therapeutic efficacy for erectile dysfunction while minimizing adverse effects related to drug accumulation in patients with severely impaired kidney function. Other studies, such as those published in 2009 and 2013, also support the use of phosphodiesterase type 5 inhibitors, including tadalafil, in patients with ESRD, but the 2017 study provides the most recent and relevant guidance 3, 4. Additionally, general management of ESRD patients involves controlling blood pressure, monitoring for signs of protein-energy wasting and malnutrition, and providing vaccination against seasonal influenza, tetanus, hepatitis B, human papillomavirus, and Streptococcus pneumoniae 5, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.